Accustem Sciences Inc (ACUT) USD0.001

Sell:$0.33Buy:$0.33$0.00 (1.28%)

Prices delayed by at least 15 minutes
Sell:$0.33
Buy:$0.33
Change:$0.00 (1.28%)
Deal now
Prices delayed by at least 15 minutes
Sell:$0.33
Buy:$0.33
Change:$0.00 (1.28%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

AccuStem Sciences, Inc. is a clinical-stage diagnostics company. The Company is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. The Company's product candidate is StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. In addition, the Company is focused on offering ancillary commodity testing (hereditary genetic testing, somatic mutation testing) that augments its assays and provides additional information to patients and physicians throughout the patient care continuum. The Company also holds licensing rights for the MicroRNA Signature Classifier (MSC) test, which is designed to help determine whether lung nodules identified by low-dose computed tomography (LDCT) screening are benign or malignant. The Company's wholly owned subsidiary is StemPrintER Sciences Limited.

Key people

Wendy Blosser
Chief Executive Officer, Director
Keeren Shah
Chief Financial Officer
Jeff Fensterer
Chief Operating Officer
Joe Flanagan
Chief Business Officer
Gabriele Marco Antonio Cerrone
Director
John Brancaccio
Independent Director
Sean McDonald
Independent Director
Willy Simon
Independent Director
Click to see more

Key facts

  • EPIC
    ACUT
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US00444A1016
  • Market cap
    $3.97m
  • Employees
    3
  • Shares in issue
    11.35m
  • Exchange
    Over The Counter
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.